VG Value

Micron Completes Acquisition of PSMC's Tonglu Plant and Plans Expansion

RBA Expected to Raise Rates in March to Address Inflation Pressure

Buffett's Shareholder Letters Create Writing Pressure for New CEO Abel

Chilton Investment Co. Inc. increased its stake in Home Depot to 667,398 shares

Investor Duan Yongping significantly increases holdings in AI-related stocks, drawing a strategic comparison to Buffett

Mixed Analyst Sentiment on Berkshire Hathaway (BRK-B) Amid Cashflow Concerns

Micron Technology to Report Q2 FY2026 Earnings on March 18

Home Depot Enhances Customer Experience Through Real-Time Tracking of Large Commodities and Receives Buy Rating

Berkshire Hathaway Repurchases $225 Million in Shares

Berkshire Hathaway files annual proxy statement detailing share buybacks and executive compensation

Analyst highlights Berkshire Hathaway's significant income from Coca-Cola dividends

Fund managed by prominent investor Duan Yongping increased its stake in Berkshire Hathaway in Q4 2025

Analyst believes Berkshire Hathaway remains a premier conglomerate during leadership transition

Berkshire Hathaway Faces Insurance Headwinds as Underwriting Profits Declined in 2025

US Bank International President Sells Company Common Stock

Berkshire Hathaway Announces 2025 Executive Compensation

NetEase Analysis: Buffett's Final Homework Before Retirement Reveals Strategy to Invest in Tangible and Industrial Companies

Analysis indicates Buffett shifted to 'Heavy Asset, Low Obsolescence' industries before retirement

Johnson & Johnson's New Drug Erda-iDRS Shows Positive Early Results

JPMorgan and Partners Group Cancel UAE Events

bioAffinity Tech

Firefly Neuroscience

Silvaco

eLong Power

T-REX 2X Long UPXI Daily Target ETF

Polaryx Therapeutics

TCW Strategic Income Fund, Inc.

Stak

iSpecimen

Oruka Therapeutics

CTNM

Contineum Therapeutics (NASDAQ:CTNM) presented its clinical priorities at the Leerink Global Healthcare Conference, highlighting a shift to a clinical-stage focus with two lead programs: PIPE-791 for idiopathic pulmonary fibrosis (IPF) and PIPE-307 partnered with Johnson & Johnson for major depressive disorder (MDD). CEO Carmine Stengone emphasized PIPE-791's potential advantages over competitors, including dosing convenience and receptor occupancy. The ongoing Phase 2 IPF trial aims for rigorous execution, while PIPE-307's Phase 2 study targets rapid-acting depression treatment. Contineum's strategy reflects a commitment to advancing its clinical pipeline.

Market Beat

Johnson & Johnson

Contineum Therapeutics

Contineum Therapeutics Highlights PIPE-791 IPF Trial, J&J-Backed PIPE-307 Catalysts at Leerink Conference

GAMR

HERO

ESPO

JPMorgan Chase & Co. is preparing to offload over $30 billion in junk bonds and leveraged loans, including deals for Electronic Arts and Sealed Air, amid market uncertainties. CEO Jamie Dimon has cautioned about a potential credit cycle downturn. Despite concerns over inflation and geopolitical tensions, JPMorgan is confident investors will find value in these offerings. Large institutional investors are expected to participate, although some deals, like Qualtrics, may face less interest. The current market environment is seen as an opportunity for investors to acquire debt at discounted prices.

Business Standard

Electronic Arts

QUALTRICS INTERNATIONAL INC

Wedbush ETFMG Video Game Tech ETF

JPMorgan Chase

Global X Video Games & Esports ETF

VanEck Video Gaming and eSport ETF

Sealed Air

Defiance Daily Target 2X Long JPM ETF

JPMorgan moves to offload over $30 bn in LBO debt amid market jitters

LABU

Coherus Oncology (NASDAQ:CHRS) presented at the Citizens Life Sciences Conference, detailing its shift to focus on immuno-oncology, led by CEO Denny Lanfear. The company has acquired Surface Oncology and divested its biosimilar assets, reducing debt by nearly $480 million. LOQTORZI, a PD-1 therapy, is projected to generate significant revenue, with sales expected to grow from $19.1 million in 2024 to $40.8 million in 2025. Additionally, tagmokitug, a CCR8-targeting molecule, is being studied in various cancers, including prostate cancer through a collaboration with Johnson & Johnson.

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

Invesco Nasdaq Biotechnology ETF

SPDR S&P Biotech

iShares Global Healthcare

Coherus Oncology

VG Health

Coherus Oncology Pivots to Immuno-Oncology, Touts LOQTORZI Growth and New Pipeline at Citizens Conf.

Reuters

JPMorgan, Partners Group Cancel Uae Events As Iran War Drags On - Bloomberg News

VTWV

FNCL

Atlanticus Holdings’ Earnings Call Highlights Transformative Growth

Tip Ranks

ISHRS Russ 2000 Val

VG Growth

Vanguard Russell 2000 Value

iShares Core S&P US Value

Financial Select Sector SPDR Fund

Vanguard Russell 2000 Growth

Ps S&P Low Vol

VG Financial

Atlanticus

ISHRS Russ Microcap

VG S-Cp Value

ISHRS Us Brokers & Sec Exchg

SPDR S&P 600 S-Cp Val

ISHRS Russ 2000 Growth

Avantis US Large Cap Value ETF

Wtree Us S-Cp Fund

Direxion Small Cap Bull 3X

VG S&P M-Cap 400 Val

Pro Rsl 2000 Dvd Grw

Vanguard Russell 2000

Invesco S&P 500 Eq Wgt ETF

Dimensional US Targeted Value ETF

iShares MSCI USA Value Factor ETF

Avantis US Small Cap Equity ETF

EA Bridgeway Omni Small-Cap Value ETF

VG Mid-Cap Val

Fidelity MSCI Financials Index

iShares Russell 2000

Avantis U.S. Small Cap Value

Atlanticus Holdings’ Earnings Call Highlights Transformative Growth

Johnson & Johnson reported promising early results from a Phase 1 study of Erda-iDRS, a drug-releasing bladder insert containing erdafitinib, for patients with intermediate- and high-risk non-muscle invasive bladder cancer. The study met its primary safety goal and showed complete responses in intermediate-risk patients, with encouraging recurrence-free responses in high-risk patients. The findings support further development, with Phase 2 and Phase 3 studies planned. The stock price is currently at $243.42, reflecting a change of +1.38 (+0.57%).

Fidelity

Johnson & Johnson Reports Promising Early Data for Erdafitinib Bladder Insert in Early Study

Diversify Advisory Services LLC has reduced its stake in JPMorgan Chase & Co. by 17.4%, selling 7,058 shares during the third quarter, leaving them with 33,500 shares valued at $10.36 million. Other investors, including Brighton Jones LLC and Acorns Advisers LLC, have also adjusted their holdings in JPM. Despite a recent upgrade to "Strong Buy" by Zacks, JPMorgan faces challenges including markdowns in private-credit portfolios and a proposed class-action lawsuit related to a crypto Ponzi scheme, contributing to negative sentiment around the stock.

Diversify Advisory Services LLC Sells 7,058 Shares of JPMorgan Chase & Co. $JPM

AMZU

ONLN

EBIZ

IBUY

AMZN

- Target's new CEO, Michael Fiddelke, implemented price cuts on over 3,000 products to boost sales amid increasing competition from Walmart and others.  
- His strategy includes a $6 billion budget with a focus on AI and trendy apparel, as well as improvements in supply chain efficiency, although analysts warn that success may take time.  
- Target's revenues have declined for five consecutive quarters, and the effectiveness of Fiddelke's turnaround initiatives remains uncertain, raising concerns among investors about the company's future performance.

Target

VanEck Retail ETF

SPDR S&P Retail ETF

Direxion Daily AMZN Bull 2X Shares

Walmart

ProShares Online Retail

Global X E-commerce ETF

Amplify Online Retail ETF

Amazon

ANALYSIS-New Target CEO slashes prices. Previous cuts offered short-lived sales boost.

BRKU

BRKD

BRK.B

BRK.A

Warren Buffett’s Berkshire Hathaway has reduced its stake in Bank of America (NYSE:BAC) by approximately 50% as he approaches retirement. This significant reduction diminishes the influence of a prominent shareholder who first invested in 2011. The move aligns with Berkshire's shift towards other sectors. Investors are now questioning the implications of this change on risk and capital allocation. Bank of America, a major player in consumer banking and wealth management, faces evolving market conditions, including tighter regulations and digital banking trends. Analysts note the stock is currently undervalued compared to its target price.

- Warren Buffett's Berkshire Hathaway has reduced its stake in Bank of America by approximately 50%, signaling a shift in investment strategy ahead of Buffett's retirement.  
- This reduction could influence perceptions of risk and capital allocation among investors, particularly as Bank of America navigates a changing banking landscape marked by regulatory pressures and digital transformation.  
- Current and prospective shareholders should monitor valuation metrics and insider trading trends to better understand the potential impacts on the bank's future performance.

Simplywall

Direxion Daily BRKB Bull 2X Shares

Direxion Daily BRKB Bear 1X Shares

Berkshire Hathaway B

Berkshire Hathaway

Buffett Exit Cuts Bank Of America Stake As Valuation Debate Grows

- Berkshire Hathaway disclosed that CEO Greg Abel received $22 million in compensation last year and executed buybacks exceeding $200 million, marking its first since May 2024.  
- The company aims to repurchase shares when their intrinsic value exceeds market price, which Abel highlighted during a CNBC interview amid concerns about Berkshire's cautious investment approach.  
- Berkshire's board supports a shareholder advisory vote on executive compensation but opposes a proposal for workforce oversight, arguing that each operating unit should manage its own affairs.

Berkshire awards CEO Abel $22 million for 2025, confirms it resumed stock buybacks

XOMX

- U.S. energy company shares rose premarket as crude prices increased, with Brent crude up 5.33% at $96.88 per barrel and West Texas Intermediate crude rising 4.89% to $91.52.  
- The rise in oil prices is attributed to escalated attacks by Iran on oil and transport facilities in the Middle East, raising fears of prolonged conflict and potential disruptions in oil flows through the Strait of Hormuz.  
- Major oil companies like Exxon Mobil and Chevron reported gains of 0.8%, while other companies saw increases ranging from 1.2% to 2.2%.

Chevron

VanEck Oil Services ETF

Exxon Mobil

Murphy Oil

VG Energy

GLOBAL X MLP & Energy Infra

Halliburton

ISHRS S&P Glb Engy

iShares US Oil & Gas Expl & Prod

SPDR O&G Equip

SPDR Energy Select

VanEck Oil Refiners ETF

SPDR O&G Ex & Prd

Global X MLP

Alerian MLP

iShares US Oil Equip & Svcs

Direxion Daily XOM Bull 2X Shares

Occidental Petroleum

Direxion Daily Energy Bull 2X

Marathon Petroleum

BUZZ-US energy companies rise as Iran escalates attacks on Gulf shipping

07777

Berkshire Hathaway confirms it resumed stock buybacks in Q1, repurchasing the equivalent of about 309 Class A shares through March 4, SEC filing shows

marketscreener

XL2CSOPBRKB

Berkshire Hathaway confirms it resumed stock buybacks in Q1, repurchasing the equivalent of about 309 Class A shares through March 4, SEC filing shows

UPRO

S&P Closes Out Third Straight Week of Loses | Closing Bell

iShares Core S&P 500

Pro UltrPro S&Pro 500

VG Mga Cap 300 Grw

SPDR S&P 500

S&P 500

Schw Us L-Cp Grw

Ultr S&P 500 Pro

VG S&P 500

VG Mga Cap 300 Val

iShares Core S&P US Growth

SPDR Portfolio S&P 500 ETF

Direxion S&P 500 Bull 3X

S&P Closes Out Third Straight Week of Loses | Closing Bell

XOMZ

Exxon Mobil Corporation (NYSE:XOM) aims for a 13% earnings growth through 2030, as presented at the Morgan Stanley Energy & Power Conference 2026. The company is also recognized as one of the 14 safe stocks for a starter portfolio.

- Exxon Mobil Corporation (NYSE:XOM) is identified as one of 14 safe stocks suitable for beginner portfolios.  
- The company shared its financial outlook during the Morgan Stanley Energy & Power Conference 2026 on March 3, outlining its objectives for sustained growth.  
- Exxon anticipates a 13% compound annual growth rate in earnings moving forward.

Direxion Daily XOM Bear 1X Shares

Exxon Mobil Corporation (XOM) targets 13% earnings growth through 2030

JPMorgan Chase has lowered the collateral valuation for software loans and tightened lending to private credit institutions to reduce risk exposure. This measure is seen as a proactive risk control in response to the volatility in the private credit market and the software industry. The adjustment stems from changes in market valuations, with no actual loan losses reported. JPMorgan Chase CEO Jamie Dimon has long warned about credit risks, and this action continues the bank's prudent risk control approach, reflecting a reassessment of risks associated with high-leverage lending

腾讯新闻 - 财经

JPMorgan Chase lowers software loan valuations and tightens private credit financing to mitigate risks

The daily swings in the S&amp;P500 are thinning, as the overall trend is downwards.

Bosera S&P 500 ETF

ISHRS Russ 1000 Growth

Guotai S&P 500 ETF(QDII)

Fidelity Nasdaq Composite Index ETF

- U.S. stocks experienced a mixed day, with the Dow and S&P 500 declining while the Nasdaq gained slightly amidst concerns over military tensions with Iran and economic stagflation.  
- Oil prices dropped significantly, influenced by Iran's threats of an oil blockade and the ongoing geopolitical conflict, while Oracle's shares rose after a positive earnings report.  
- The market is bracing for upcoming economic data that may further impact trading sentiment.

US STOCKS-Wall St closes mixed on ramped-up Middle East tensions

Accidentally saw it and thought it was worth sharing...

The 10 Best ETFs in the U.S. Stock Market

VG Value(VTV.US)

Contineum Therapeutics Highlights PIPE-791 IPF Trial, J&J-Backed PIPE-307 Catalysts at Leerink Conference

JPMorgan moves to offload over $30 bn in LBO debt amid market jitters

Coherus Oncology Pivots to Immuno-Oncology, Touts LOQTORZI Growth and New Pipeline at Citizens Conf.

JPMorgan, Partners Group Cancel Uae Events As Iran War Drags On - Bloomberg News

Atlanticus Holdings’ Earnings Call Highlights Transformative Growth